| Id: | acc3279 |
| Group: | 2sens |
| Protein: | Tau |
| Gene Symbol: | MAPT |
| Protein Id: | P10636 |
| Protein Name: | TAU_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser202 |
| Site Sequence: | LGDLHQEGPPLKGAGGKERPG |
| Disease Category: | Nervous system diseases |
| Disease: | Alzheimer's Disease |
| Disease Subtype: | |
| Disease Cellline: | N2aSwe? |
| Disease Info: | |
| Drug: | Cilostazol + resveratrol |
| Drug Info: | "Cilostazol is a medication used to treat intermittent claudication by improving blood flow. | Resveratrol is a natural compound with potential health benefits, including antioxidant and anti - inflammatory properties. " |
| Effect: | modulate |
| Effect Info: | Cilostazol reduces Aβ-induced tau phosphorylation levels and exerts an anti-tauopathy effect by downregulating the expression of GSK3β P-Tyr216. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 24254769 |
| Sentence Index: | 24254769_1-2 |
| Sentence: | "beta-Amyloid (Abeta) deposits and hyperphosphorylated tau aggregates are the chief hallmarks in the Alzheimer's disease (AD) brains, but the strategies for controlling these pathological events remain elusive. We hypothesized that CK2-coupled SIRT1 activation stimulated by cilostazol suppresses tau acetylation (Ac-tau) and tau phosphorylation (P-tau) by inhibiting activation of P300 and GSK3beta." |
Sequence & Structure:
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MAPT | TILAVONEMAB | Microtubule-associated protein tau inhibitor | 2 | Terminated | Alzheimer disease | ClinicalTrials |
| MAPT | ZAGOTENEMAB | Microtubule-associated protein tau inhibitor | 2 | Completed | Alzheimer disease | ClinicalTrials |
| MAPT | SEMORINEMAB | Microtubule-associated protein tau inhibitor | 2 | Completed | Alzheimer disease | ClinicalTrials |
| MAPT | BEPRANEMAB | Microtubule-associated protein tau inhibitor | 2 | Active, not recruiting | Alzheimer disease | ClinicalTrials |
| MAPT | GOSURANEMAB | Microtubule-associated protein tau inhibitor | 2 | Terminated | Alzheimer disease | ClinicalTrials |
| MAPT | TILAVONEMAB | Microtubule-associated protein tau inhibitor | 2 | Completed | Alzheimer disease | ClinicalTrials |
| MAPT | SEMORINEMAB | Microtubule-associated protein tau inhibitor | 2 | Terminated | Alzheimer disease | ClinicalTrials |
| MAPT | TILAVONEMAB | Microtubule-associated protein tau inhibitor | 2 | Terminated | progressive supranuclear palsy | ClinicalTrials ClinicalTrials |
| MAPT | GOSURANEMAB | Microtubule-associated protein tau inhibitor | 2 | Terminated | Classical progressive supranuclear palsy | ClinicalTrials |
| MAPT | SEMORINEMAB | Microtubule-associated protein tau inhibitor | 1 | Completed | Alzheimer disease | ClinicalTrials |
| MAPT | POSDINEMAB | Microtubule-associated protein tau inhibitor | 1 | Completed | Alzheimer disease | ClinicalTrials |
| MAPT | ZAGOTENEMAB | Microtubule-associated protein tau inhibitor | 1 | Completed | Alzheimer disease | ClinicalTrials ClinicalTrials |
| MAPT | GOSURANEMAB | Microtubule-associated protein tau inhibitor | 1 | Completed | progressive supranuclear palsy | ClinicalTrials |
| MAPT | TILAVONEMAB | Microtubule-associated protein tau inhibitor | 1 | Completed | progressive supranuclear palsy | ClinicalTrials |
| MAPT | BEPRANEMAB | Microtubule-associated protein tau inhibitor | 1 | Active, not recruiting | progressive supranuclear palsy | ClinicalTrials |
| MAPT | BEPRANEMAB | Microtubule-associated protein tau inhibitor | 1 | Completed | progressive supranuclear palsy | ClinicalTrials |
| MAPT | GOSURANEMAB | Microtubule-associated protein tau inhibitor | 1 | Terminated | Classical progressive supranuclear palsy | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| MAPT-Ser157 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser171 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.695 | ||||
| HGSC | 0.803 | ||||
| ccRCC | -0.414 | ||||
| GBM | -0.201 | ||||
| HNSC | -0.351 | ||||
| LUAD | 0.238 | ||||
| LUSC | 0.654 | ||||
| non_ccRCC | -2.3 | ||||
| PDAC | 0.875 | ||||
| UCEC | |||||
| MAPT-Ser214 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.404 | ||||
| COAD | -0.453 | ||||
| HGSC | |||||
| ccRCC | -0.044 | ||||
| GBM | |||||
| HNSC | -0.906 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser221 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser222 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser227 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.288 | ||||
| HGSC | |||||
| ccRCC | -0.912 | ||||
| GBM | |||||
| HNSC | -0.66 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 1.284 | ||||
| MAPT-Ser228 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.16 | ||||
| COAD | 0.877 | ||||
| HGSC | |||||
| ccRCC | 0.434 | ||||
| GBM | 0.509 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.661 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser232 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.136 | ||||
| HGSC | |||||
| ccRCC | -0.391 | ||||
| GBM | -0.745 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser235 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser236 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.181 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.624 | ||||
| GBM | 0.659 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.464 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser238 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -1.889 | ||||
| ccRCC | 0.147 | ||||
| GBM | 0.428 | ||||
| HNSC | 0.318 | ||||
| LUAD | 1.102 | ||||
| LUSC | 0.899 | ||||
| non_ccRCC | -1.415 | ||||
| PDAC | 0.291 | ||||
| UCEC | 0.119 | ||||
| MAPT-Ser239 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.461 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.439 | ||||
| GBM | 0.596 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.496 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser245 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.707 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser247 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.5 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -1.151 | ||||
| GBM | 0.651 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser251 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.241 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.207 | ||||
| GBM | 0.959 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.407 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser272 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.472 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.475 | ||||
| GBM | 0.552 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.499 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser299 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -0.707 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser318 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.766 | ||||
| COAD | -0.028 | ||||
| HGSC | |||||
| ccRCC | -0.519 | ||||
| GBM | 1.366 | ||||
| HNSC | 0.252 | ||||
| LUAD | -0.046 | ||||
| LUSC | |||||
| non_ccRCC | -1.792 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser361 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.398 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.15 | ||||
| GBM | 0.881 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.429 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser393 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.1 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 1.046 | ||||
| GBM | -0.946 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser433 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.642 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.264 | ||||
| GBM | 0.574 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.48 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser437 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.489 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.602 | ||||
| GBM | 0.709 | ||||
| HNSC | -0.101 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.699 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser441 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.707 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser446 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.842 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.263 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.105 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser450 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser453 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser46 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser501 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.154 | ||||
| HGSC | |||||
| ccRCC | -0.55 | ||||
| GBM | -0.604 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser502 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.517 | ||||
| HGSC | |||||
| ccRCC | 0.636 | ||||
| GBM | -1.153 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser508 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.055 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.659 | ||||
| GBM | 0.717 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.431 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser512 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.683 | ||||
| HGSC | |||||
| ccRCC | 0.227 | ||||
| GBM | 0.117 | ||||
| HNSC | -0.257 | ||||
| LUAD | -1.369 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.401 | ||||
| MAPT-Ser515 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.763 | ||||
| HGSC | |||||
| ccRCC | -0.429 | ||||
| GBM | -0.171 | ||||
| HNSC | -0.62 | ||||
| LUAD | -0.542 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser516 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.173 | ||||
| COAD | 0.594 | ||||
| HGSC | -0.787 | ||||
| ccRCC | 0.494 | ||||
| GBM | 0.548 | ||||
| HNSC | 0.444 | ||||
| LUAD | -0.275 | ||||
| LUSC | 0.648 | ||||
| non_ccRCC | -2.658 | ||||
| PDAC | 0.677 | ||||
| UCEC | 0.489 | ||||
| MAPT-Ser519 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.311 | ||||
| COAD | 0.632 | ||||
| HGSC | 0.192 | ||||
| ccRCC | 0.278 | ||||
| GBM | 0.512 | ||||
| HNSC | 0.633 | ||||
| LUAD | -1.129 | ||||
| LUSC | 0.027 | ||||
| non_ccRCC | -2.605 | ||||
| PDAC | 0.541 | ||||
| UCEC | 0.61 | ||||
| MAPT-Ser525 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.031 | ||||
| COAD | 0.36 | ||||
| HGSC | -1.344 | ||||
| ccRCC | |||||
| GBM | -0.047 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser527 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.351 | ||||
| COAD | |||||
| HGSC | 0.621 | ||||
| ccRCC | -1.491 | ||||
| GBM | 0.519 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser531 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.019 | ||||
| COAD | |||||
| HGSC | -0.1 | ||||
| ccRCC | -0.061 | ||||
| GBM | 0.88 | ||||
| HNSC | -0.085 | ||||
| LUAD | 0.454 | ||||
| LUSC | 1.226 | ||||
| non_ccRCC | -2.083 | ||||
| PDAC | 0.928 | ||||
| UCEC | -1.139 | ||||
| MAPT-Ser552 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.159 | ||||
| COAD | 1.489 | ||||
| HGSC | |||||
| ccRCC | 0.164 | ||||
| GBM | 0.266 | ||||
| HNSC | -0.276 | ||||
| LUAD | -0.161 | ||||
| LUSC | -0.178 | ||||
| non_ccRCC | -2.455 | ||||
| PDAC | 0.567 | ||||
| UCEC | 0.426 | ||||
| MAPT-Ser56 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser579 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.089 | ||||
| HGSC | -0.728 | ||||
| ccRCC | |||||
| GBM | 0.277 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.642 | ||||
| PDAC | 0.55 | ||||
| UCEC | 0.455 | ||||
| MAPT-Ser61 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.834 | ||||
| COAD | 0.982 | ||||
| HGSC | |||||
| ccRCC | 0.26 | ||||
| GBM | -1.279 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -0.797 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser641 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.19 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.431 | ||||
| GBM | 0.28 | ||||
| HNSC | 0.946 | ||||
| LUAD | 0.649 | ||||
| LUSC | 0.713 | ||||
| non_ccRCC | -1.968 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser673 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.613 | ||||
| COAD | 0.268 | ||||
| HGSC | 1.254 | ||||
| ccRCC | 0.696 | ||||
| GBM | -1.579 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.026 | ||||
| MAPT-Ser713 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.182 | ||||
| COAD | 0.324 | ||||
| HGSC | |||||
| ccRCC | -0.223 | ||||
| GBM | 0.109 | ||||
| HNSC | 0.89 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -2.088 | ||||
| PDAC | |||||
| UCEC | 0.806 | ||||
| MAPT-Ser717 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.265 | ||||
| COAD | 0.532 | ||||
| HGSC | |||||
| ccRCC | -0.058 | ||||
| GBM | -0.074 | ||||
| HNSC | 0.631 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -2.262 | ||||
| PDAC | 0.712 | ||||
| UCEC | 0.784 | ||||
| MAPT-Ser721 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.283 | ||||
| COAD | 0.389 | ||||
| HGSC | -1.986 | ||||
| ccRCC | |||||
| GBM | 0.032 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | 0.61 | ||||
| UCEC | 0.673 | ||||
| MAPT-Ser726 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.825 | ||||
| COAD | 0.013 | ||||
| HGSC | |||||
| ccRCC | 0.086 | ||||
| GBM | |||||
| HNSC | 0.739 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.663 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser730 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.308 | ||||
| HGSC | |||||
| ccRCC | -0.81 | ||||
| GBM | 1.118 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser733 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Ser84 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.081 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.304 | ||||
| GBM | 0.459 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.236 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr212 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.277 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 1.47 | ||||
| GBM | -0.758 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -0.436 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr218 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.251 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.662 | ||||
| GBM | 0.564 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.477 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr242 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.221 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.697 | ||||
| GBM | 0.927 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -0.403 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr249 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.753 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.212 | ||||
| GBM | 0.498 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.463 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr254 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.278 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.814 | ||||
| GBM | 0.366 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.458 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr257 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr268 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.388 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.699 | ||||
| GBM | 0.397 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.484 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr414 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.882 | ||||
| GBM | 0.205 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.087 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr423 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr451 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr492 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.538 | ||||
| COAD | 1.639 | ||||
| HGSC | |||||
| ccRCC | 0.269 | ||||
| GBM | -0.76 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -0.611 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr498 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.256 | ||||
| COAD | 0.705 | ||||
| HGSC | 0.297 | ||||
| ccRCC | 0.376 | ||||
| GBM | 0.225 | ||||
| HNSC | 0.256 | ||||
| LUAD | 0.385 | ||||
| LUSC | 0.133 | ||||
| non_ccRCC | -2.913 | ||||
| PDAC | 0.649 | ||||
| UCEC | 0.145 | ||||
| MAPT-Thr52 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.991 | ||||
| GBM | -0.941 | ||||
| HNSC | -1.208 | ||||
| LUAD | |||||
| LUSC | 0.605 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.554 | ||||
| MAPT-Thr522 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -2.399 | ||||
| COAD | 0.89 | ||||
| HGSC | -0.286 | ||||
| ccRCC | 0.473 | ||||
| GBM | 0.818 | ||||
| HNSC | -0.28 | ||||
| LUAD | 0.29 | ||||
| LUSC | 0.608 | ||||
| non_ccRCC | -1.174 | ||||
| PDAC | 0.477 | ||||
| UCEC | 0.583 | ||||
| MAPT-Thr529 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.623 | ||||
| COAD | 0.041 | ||||
| HGSC | 0.48 | ||||
| ccRCC | -0.112 | ||||
| GBM | 0.276 | ||||
| HNSC | |||||
| LUAD | 0.615 | ||||
| LUSC | |||||
| non_ccRCC | -2.387 | ||||
| PDAC | 0.464 | ||||
| UCEC | |||||
| MAPT-Thr534 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.063 | ||||
| COAD | -1.759 | ||||
| HGSC | -0.176 | ||||
| ccRCC | 0.533 | ||||
| GBM | 0.14 | ||||
| HNSC | 0.668 | ||||
| LUAD | 1.07 | ||||
| LUSC | |||||
| non_ccRCC | -1.459 | ||||
| PDAC | 0.92 | ||||
| UCEC | |||||
| MAPT-Thr537 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.793 | ||||
| GBM | 0.47 | ||||
| HNSC | -0.29 | ||||
| LUAD | 0.652 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -1.625 | ||||
| MAPT-Thr548 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.148 | ||||
| COAD | 0.936 | ||||
| HGSC | |||||
| ccRCC | 0.61 | ||||
| GBM | 0.162 | ||||
| HNSC | -0.174 | ||||
| LUAD | -0.008 | ||||
| LUSC | -0.163 | ||||
| non_ccRCC | -2.638 | ||||
| PDAC | 0.725 | ||||
| UCEC | 0.402 | ||||
| MAPT-Thr580 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr69 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 1.015 | ||||
| GBM | -0.03 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -0.985 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr694 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.882 | ||||
| GBM | 0.205 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -1.087 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr703 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr720 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr731 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Thr82 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Tyr234 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Tyr431 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.83 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -1.11 | ||||
| GBM | 0.28 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPT-Tyr514 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.665 | ||||
| GBM | 0.585 | ||||
| HNSC | -0.031 | ||||
| LUAD | 0.503 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -1.721 | ||||
| MAPT-Tyr711 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.663 |
| COAD | |
| HGSC | |
| ccRCC | -1.435 |
| GBM | 0.068 |
| HNSC | 0.704 |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 202 | D | Dementia with Lewy bodies | Phosphorylation | 34983390 |
| S | 202 | P | Alzheimer's disease | Phosphorylation | 15517432 |
| S | 202 | U | Cardiomyopathy | Phosphorylation | 37429912 |
| S | 202 | U | Myocardial infarction | Phosphorylation | 37429912 |
| S | 202 | U | Niemann-pick disease | Phosphorylation | 34536819 |
| S | 202 | U | Parkinson's disease | Phosphorylation | 24073234 ; 24073234 ; 34983390 |
| S | 202 | U | Progressive supranuclear palsy | Phosphorylation | 18315566 |
| T | 202 | U | Chronic traumatic encephalopathy | Phosphorylation | 34854540 |
| S | 202 | U | Alzheimer's disease | Phosphorylation | 18725412 ; 19451179 ; 33469985 ; 8506352 ; 18725412 ; 19451179 ; 24757378 ; 24073234 ; 28814543 ; 33730588 ; 33649324 ; 34 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
